Novavax, Inc. (NASDAQ:NVAX) was the target of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 48,625,485 shares, a growth of 5.5% from the February 15th total of 46,071,037 shares. Based on an average trading volume of 13,194,189 shares, the days-to-cover ratio is presently 3.7 days. Approximately 18.6% of the shares of the company are short sold.
Novavax (NASDAQ:NVAX) opened at $2.06 on Friday. The company has a quick ratio of 3.31, a current ratio of 3.31 and a debt-to-equity ratio of -4.28. Novavax has a 1-year low of $0.73 and a 1-year high of $2.75. The company has a market capitalization of $652.38, a price-to-earnings ratio of -3.03 and a beta of 2.49.
A number of research firms recently weighed in on NVAX. B. Riley set a $10.00 target price on Novavax and gave the stock a “buy” rating in a report on Thursday, January 11th. Ladenburg Thalmann Financial Services boosted their target price on Novavax to $2.50 and gave the stock a “buy” rating in a report on Thursday, January 11th. S&P Equity Research decreased their target price on Novavax from $1.81 to $1.35 in a report on Wednesday, January 10th. Citigroup lowered Novavax from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a report on Tuesday, December 19th. Finally, Chardan Capital reissued a “hold” rating on shares of Novavax in a report on Thursday, March 1st. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $3.11.
COPYRIGHT VIOLATION WARNING: “Novavax, Inc. (NVAX) Sees Significant Increase in Short Interest” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3254291/novavax-inc-nvax-sees-significant-increase-in-short-interest.html.
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.